HTRA3

Across TCGA pan-cancer cohorts, HTRA3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HTRA3 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HTRA3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HTRA3 expression acts as an unfavorable survival marker.

PDAC, LSCC, and LUAD are the cancer types where HTRA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.624	1.000	<.001	52	view →
LSCC	DFS	Median	All	0.580	0.839	.001	32	view →
LUAD	OS	Tertile	II,III,IV	0.419	0.750	.009	12	view →
UCEC	DFS	Median	All	0.860	0.976	.012	12	view →
HNSC	OS	Median	All	0.606	0.803	.006	11	view →
CCRCC	OS	Median	All	0.332	0.934	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HTRA3–PDAC (OS)

Open the PDAC breakdown →